FUSN Description — Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Co. has developed its Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology to enable them to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Co. serves health care sectors in Canada.
|
|
Free FUSN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|